Decitabine triphosphate levels in peripheral blood mononuclear cells from patients receiving prolonged low-dose decitabine administration: a pilot study View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2012-03-01

AUTHORS

Robert S. Jansen, Hilde Rosing, Pierre W. Wijermans, Ron J. Keizer, Jan H. M. Schellens, Jos H. Beijnen

ABSTRACT

PurposeDecitabine is a nucleoside analog used in the treatment for myelodysplastic syndrome. The compound requires intracellular conversion to its triphosphate to become active. Decitabine triphosphate has, however, never been quantified in peripheral blood mononuclear cells (PBMCs) from patients.MethodThis article describes a method for the quantitative determination of decitabine triphosphate in PBMCs using liquid chromatography coupled to tandem mass spectrometry. The method was applied to ex vivo incubated whole blood samples and samples from three patients receiving prolonged low-dose decitabine treatment.ResultsWe successfully quantitated decitabine triphosphate in PBMCs. Considerable levels were detected in PBMCs from two patients that responded well to therapy, whereas only low levels were present in a non-responding patient. Moreover, the data show that, in contrast to plasma decitabine, intracellular decitabine triphosphate accumulates during a treatment cycle of nine infusions at a dose of 15 mg/m2.ConclusionsThe results suggest a relationship between decitabine triphosphate levels and response to therapy. Based on the observed accumulation of decitabine triphosphate during a treatment cycle, a less intensive dose scheme could be feasible. More... »

PAGES

1457-1466

References to SciGraph publications

  • 1995-07. In vitro-induced resistance to the deoxycytidine analogues cytarabine (AraC) and 5-aza-2′-deoxycytidine (DAC) in a rat model for acute myeloid leukemia is mediated by mutations in the deoxycytidine kinase (dck) gene in ANNALS OF HEMATOLOGY
  • 2008-04-09. Inhibition of cytidine deaminase by zebularine enhances the antineoplastic action of 5-aza-2′-deoxycytidine in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 1997-02-01. Pharmacological approach for optimization of the dose schedule of 5-Aza-2’-deoxycytidine (Decitabine) for the therapy of leukemia in LEUKEMIA
  • 1989-01. Chemotherapy of L1210 and L1210/ARA-C leukemia with 5-aza-2′-deoxycytidine and 3-deazauridine in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 1986. 5-AZA-2′-Deoxycytidine Synergistic action with Thymidine on Leukemic Cells and Interaction of 5-AZA-dCMP with dCMP Deaminase in PURINE AND PYRIMIDINE METABOLISM IN MAN V
  • 1997-01-01. Continuous infusion of low-dose 5-Aza-2′-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome in LEUKEMIA
  • 2005-11-15. In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies in ANNALS OF HEMATOLOGY
  • 2008-05-02. Importance of dose-schedule of 5-aza-2'-deoxycytidine for epigenetic therapy of cancer in BMC CANCER
  • 1998-09. Drug resistance to 5-aza-2′-deoxycytidine, 2′,2′-difluorodeoxycytidine, and cytosine arabinoside conferred by retroviral-mediated transfer of human cytidine deaminase cDNA into murine cells in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2003-02-27. Phase I trial of continuous infusion 5-aza-2′-deoxycytidine in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 1992-01. Potent inhibitors for the deamination of cytosine arabinoside and 5-aza-2′-deoxycytidine by human cytidine deaminase in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2007-06-13. Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1007/s00280-012-1850-x

    DOI

    http://dx.doi.org/10.1007/s00280-012-1850-x

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1039960563

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/22382880


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Cardiorespiratory Medicine and Haematology", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Clinical Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antimetabolites, Antineoplastic", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Azacitidine", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Chromatography, Liquid", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Decitabine", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Leukocytes, Mononuclear", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Myelodysplastic Syndromes", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Pilot Projects", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Tandem Mass Spectrometry", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Department of Pharmacy and Pharmacology, Slotervaart Hospital/The Netherlands Cancer Institute, Louwesweg 6, 1066 EC, Amsterdam, The Netherlands", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Department of Pharmacy and Pharmacology, Slotervaart Hospital/The Netherlands Cancer Institute, Louwesweg 6, 1066 EC, Amsterdam, The Netherlands"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Jansen", 
            "givenName": "Robert S.", 
            "id": "sg:person.0647446717.15", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0647446717.15"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Pharmacy and Pharmacology, Slotervaart Hospital/The Netherlands Cancer Institute, Louwesweg 6, 1066 EC, Amsterdam, The Netherlands", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Department of Pharmacy and Pharmacology, Slotervaart Hospital/The Netherlands Cancer Institute, Louwesweg 6, 1066 EC, Amsterdam, The Netherlands"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Rosing", 
            "givenName": "Hilde", 
            "id": "sg:person.01107523720.19", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01107523720.19"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Haematology, Haga Hospital, Leyweg 275, 2545 CH, The Hague, The Netherlands", 
              "id": "http://www.grid.ac/institutes/grid.413591.b", 
              "name": [
                "Department of Haematology, Haga Hospital, Leyweg 275, 2545 CH, The Hague, The Netherlands"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Wijermans", 
            "givenName": "Pierre W.", 
            "id": "sg:person.010061377417.22", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010061377417.22"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Pharmacy and Pharmacology, Slotervaart Hospital/The Netherlands Cancer Institute, Louwesweg 6, 1066 EC, Amsterdam, The Netherlands", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Department of Pharmacy and Pharmacology, Slotervaart Hospital/The Netherlands Cancer Institute, Louwesweg 6, 1066 EC, Amsterdam, The Netherlands"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Keizer", 
            "givenName": "Ron J.", 
            "id": "sg:person.01306226720.74", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01306226720.74"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Pharmaceutical Sciences, Science Faculty, Utrecht University, Universiteitsweg 99, 3584 CG, Utrecht, The Netherlands", 
              "id": "http://www.grid.ac/institutes/grid.5477.1", 
              "name": [
                "Division of Medical Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands", 
                "Department of Pharmaceutical Sciences, Science Faculty, Utrecht University, Universiteitsweg 99, 3584 CG, Utrecht, The Netherlands"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Schellens", 
            "givenName": "Jan H. M.", 
            "id": "sg:person.013575273137.17", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013575273137.17"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Pharmaceutical Sciences, Science Faculty, Utrecht University, Universiteitsweg 99, 3584 CG, Utrecht, The Netherlands", 
              "id": "http://www.grid.ac/institutes/grid.5477.1", 
              "name": [
                "Department of Pharmacy and Pharmacology, Slotervaart Hospital/The Netherlands Cancer Institute, Louwesweg 6, 1066 EC, Amsterdam, The Netherlands", 
                "Department of Pharmaceutical Sciences, Science Faculty, Utrecht University, Universiteitsweg 99, 3584 CG, Utrecht, The Netherlands"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Beijnen", 
            "givenName": "Jos H.", 
            "id": "sg:person.01167077171.09", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01167077171.09"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1007/978-1-4684-1248-2_24", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1033527280", 
              "https://doi.org/10.1007/978-1-4684-1248-2_24"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf00686478", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1014009072", 
              "https://doi.org/10.1007/bf00686478"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00280-007-0531-7", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1019990216", 
              "https://doi.org/10.1007/s00280-007-0531-7"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf01696231", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1005652888", 
              "https://doi.org/10.1007/bf01696231"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00280-002-0563-y", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1075257700", 
              "https://doi.org/10.1007/s00280-002-0563-y"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.leu.2400550", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1034237061", 
              "https://doi.org/10.1038/sj.leu.2400550"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s002800050832", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1023712398", 
              "https://doi.org/10.1007/s002800050832"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/1471-2407-8-128", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1027980014", 
              "https://doi.org/10.1186/1471-2407-8-128"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf00694338", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1023618222", 
              "https://doi.org/10.1007/bf00694338"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.leu.2400526", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1004603814", 
              "https://doi.org/10.1038/sj.leu.2400526"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00280-008-0750-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1052771263", 
              "https://doi.org/10.1007/s00280-008-0750-6"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00277-005-0004-1", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1023684211", 
              "https://doi.org/10.1007/s00277-005-0004-1"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2012-03-01", 
        "datePublishedReg": "2012-03-01", 
        "description": "PurposeDecitabine is a nucleoside analog used in the treatment for myelodysplastic syndrome. The compound requires intracellular conversion to its triphosphate to become active. Decitabine triphosphate has, however, never been quantified in peripheral blood mononuclear cells (PBMCs) from patients.MethodThis article describes a method for the quantitative determination of decitabine triphosphate in PBMCs using liquid chromatography coupled to tandem mass spectrometry. The method was applied to ex vivo incubated whole blood samples and samples from three patients receiving prolonged low-dose decitabine treatment.ResultsWe successfully quantitated decitabine triphosphate in PBMCs. Considerable levels were detected in PBMCs from two patients that responded well to therapy, whereas only low levels were present in a non-responding patient. Moreover, the data show that, in contrast to plasma decitabine, intracellular decitabine triphosphate accumulates during a treatment cycle of nine infusions at a dose of 15\u00a0mg/m2.ConclusionsThe results suggest a relationship between decitabine triphosphate levels and response to therapy. Based on the observed accumulation of decitabine triphosphate during a treatment cycle, a less intensive dose scheme could be feasible.", 
        "genre": "article", 
        "id": "sg:pub.10.1007/s00280-012-1850-x", 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1088364", 
            "issn": [
              "0344-5704", 
              "1432-0843"
            ], 
            "name": "Cancer Chemotherapy and Pharmacology", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "6", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "69"
          }
        ], 
        "keywords": [
          "peripheral blood mononuclear cells", 
          "blood mononuclear cells", 
          "mononuclear cells", 
          "treatment cycles", 
          "low-dose decitabine treatment", 
          "non-responding patients", 
          "triphosphate levels", 
          "whole blood samples", 
          "myelodysplastic syndrome", 
          "dose scheme", 
          "decitabine administration", 
          "blood samples", 
          "patients", 
          "decitabine treatment", 
          "pilot study", 
          "only low levels", 
          "nucleoside analogues", 
          "intracellular conversion", 
          "therapy", 
          "MethodThis article", 
          "treatment", 
          "low levels", 
          "tandem mass spectrometry", 
          "triphosphate", 
          "cells", 
          "liquid chromatography", 
          "levels", 
          "syndrome", 
          "infusion", 
          "decitabine", 
          "dose", 
          "administration", 
          "ResultsWe", 
          "vivo", 
          "observed accumulation", 
          "considerable level", 
          "response", 
          "samples", 
          "study", 
          "mass spectrometry", 
          "accumulation", 
          "contrast", 
          "accumulates", 
          "cycle", 
          "analogues", 
          "data", 
          "chromatography", 
          "relationship", 
          "quantitative determination", 
          "method", 
          "results", 
          "compounds", 
          "spectrometry", 
          "article", 
          "determination", 
          "conversion", 
          "scheme"
        ], 
        "name": "Decitabine triphosphate levels in peripheral blood mononuclear cells from patients receiving prolonged low-dose decitabine administration: a pilot study", 
        "pagination": "1457-1466", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1039960563"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1007/s00280-012-1850-x"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "22382880"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1007/s00280-012-1850-x", 
          "https://app.dimensions.ai/details/publication/pub.1039960563"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-12-01T06:30", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_579.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1007/s00280-012-1850-x"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00280-012-1850-x'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00280-012-1850-x'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00280-012-1850-x'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00280-012-1850-x'


     

    This table displays all metadata directly associated to this object as RDF triples.

    249 TRIPLES      21 PREDICATES      103 URIs      82 LITERALS      16 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1007/s00280-012-1850-x schema:about N103ad176105a43cf817c9d8f08fd08e4
    2 N13ff86dfd7454af893142ce474834b69
    3 N2be0cb8c000e4a92a7373dd628920af1
    4 N3c795516422c4aeda68f6e6bc72d5ac0
    5 Nb1d7f2e85c114d2fa2479b3675821625
    6 Nd98c0de684bc44de9b601fabc2ad2798
    7 Nd9ae0db071084cd9a847b24eefd44579
    8 Neaa8edd2e63c458092482b4c92cb8e2a
    9 Nf5affb9d594c48c6868390fe641681e6
    10 anzsrc-for:11
    11 anzsrc-for:1102
    12 anzsrc-for:1103
    13 schema:author Naef518591f814ba2b987e5ccb3445557
    14 schema:citation sg:pub.10.1007/978-1-4684-1248-2_24
    15 sg:pub.10.1007/bf00686478
    16 sg:pub.10.1007/bf00694338
    17 sg:pub.10.1007/bf01696231
    18 sg:pub.10.1007/s00277-005-0004-1
    19 sg:pub.10.1007/s00280-002-0563-y
    20 sg:pub.10.1007/s00280-007-0531-7
    21 sg:pub.10.1007/s00280-008-0750-6
    22 sg:pub.10.1007/s002800050832
    23 sg:pub.10.1038/sj.leu.2400526
    24 sg:pub.10.1038/sj.leu.2400550
    25 sg:pub.10.1186/1471-2407-8-128
    26 schema:datePublished 2012-03-01
    27 schema:datePublishedReg 2012-03-01
    28 schema:description PurposeDecitabine is a nucleoside analog used in the treatment for myelodysplastic syndrome. The compound requires intracellular conversion to its triphosphate to become active. Decitabine triphosphate has, however, never been quantified in peripheral blood mononuclear cells (PBMCs) from patients.MethodThis article describes a method for the quantitative determination of decitabine triphosphate in PBMCs using liquid chromatography coupled to tandem mass spectrometry. The method was applied to ex vivo incubated whole blood samples and samples from three patients receiving prolonged low-dose decitabine treatment.ResultsWe successfully quantitated decitabine triphosphate in PBMCs. Considerable levels were detected in PBMCs from two patients that responded well to therapy, whereas only low levels were present in a non-responding patient. Moreover, the data show that, in contrast to plasma decitabine, intracellular decitabine triphosphate accumulates during a treatment cycle of nine infusions at a dose of 15 mg/m2.ConclusionsThe results suggest a relationship between decitabine triphosphate levels and response to therapy. Based on the observed accumulation of decitabine triphosphate during a treatment cycle, a less intensive dose scheme could be feasible.
    29 schema:genre article
    30 schema:isAccessibleForFree false
    31 schema:isPartOf Ne2b7c560140f42b7b24d72c313d08851
    32 Nfe488ce8dee141f78aa3c5c06fb57653
    33 sg:journal.1088364
    34 schema:keywords MethodThis article
    35 ResultsWe
    36 accumulates
    37 accumulation
    38 administration
    39 analogues
    40 article
    41 blood mononuclear cells
    42 blood samples
    43 cells
    44 chromatography
    45 compounds
    46 considerable level
    47 contrast
    48 conversion
    49 cycle
    50 data
    51 decitabine
    52 decitabine administration
    53 decitabine treatment
    54 determination
    55 dose
    56 dose scheme
    57 infusion
    58 intracellular conversion
    59 levels
    60 liquid chromatography
    61 low levels
    62 low-dose decitabine treatment
    63 mass spectrometry
    64 method
    65 mononuclear cells
    66 myelodysplastic syndrome
    67 non-responding patients
    68 nucleoside analogues
    69 observed accumulation
    70 only low levels
    71 patients
    72 peripheral blood mononuclear cells
    73 pilot study
    74 quantitative determination
    75 relationship
    76 response
    77 results
    78 samples
    79 scheme
    80 spectrometry
    81 study
    82 syndrome
    83 tandem mass spectrometry
    84 therapy
    85 treatment
    86 treatment cycles
    87 triphosphate
    88 triphosphate levels
    89 vivo
    90 whole blood samples
    91 schema:name Decitabine triphosphate levels in peripheral blood mononuclear cells from patients receiving prolonged low-dose decitabine administration: a pilot study
    92 schema:pagination 1457-1466
    93 schema:productId N41701d0b0f8549a89224b9816e04af1c
    94 N674270482eaf4f5abec1a9412922a612
    95 Ndfb3e34f38184631a26778aba596b842
    96 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039960563
    97 https://doi.org/10.1007/s00280-012-1850-x
    98 schema:sdDatePublished 2022-12-01T06:30
    99 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    100 schema:sdPublisher N0e766b2549df4910a7693ab5d8717d9a
    101 schema:url https://doi.org/10.1007/s00280-012-1850-x
    102 sgo:license sg:explorer/license/
    103 sgo:sdDataset articles
    104 rdf:type schema:ScholarlyArticle
    105 N0e766b2549df4910a7693ab5d8717d9a schema:name Springer Nature - SN SciGraph project
    106 rdf:type schema:Organization
    107 N103ad176105a43cf817c9d8f08fd08e4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    108 schema:name Chromatography, Liquid
    109 rdf:type schema:DefinedTerm
    110 N13ff86dfd7454af893142ce474834b69 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    111 schema:name Tandem Mass Spectrometry
    112 rdf:type schema:DefinedTerm
    113 N2be0cb8c000e4a92a7373dd628920af1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    114 schema:name Leukocytes, Mononuclear
    115 rdf:type schema:DefinedTerm
    116 N3c795516422c4aeda68f6e6bc72d5ac0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    117 schema:name Azacitidine
    118 rdf:type schema:DefinedTerm
    119 N41701d0b0f8549a89224b9816e04af1c schema:name pubmed_id
    120 schema:value 22382880
    121 rdf:type schema:PropertyValue
    122 N674270482eaf4f5abec1a9412922a612 schema:name doi
    123 schema:value 10.1007/s00280-012-1850-x
    124 rdf:type schema:PropertyValue
    125 N74aa5d1f6dd44a31b4162aee18dd076a rdf:first sg:person.01107523720.19
    126 rdf:rest N8a870eeb03634a73ae25e4dc4fd4958a
    127 N8a870eeb03634a73ae25e4dc4fd4958a rdf:first sg:person.010061377417.22
    128 rdf:rest Nc0a2298c0d014c2fbc5d7a596306f4f7
    129 Naef518591f814ba2b987e5ccb3445557 rdf:first sg:person.0647446717.15
    130 rdf:rest N74aa5d1f6dd44a31b4162aee18dd076a
    131 Nb1d7f2e85c114d2fa2479b3675821625 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    132 schema:name Pilot Projects
    133 rdf:type schema:DefinedTerm
    134 Nb422d8998da845668eb2643ec6e70760 rdf:first sg:person.013575273137.17
    135 rdf:rest Nc4aa5e5718514f41ad584edcd55bfc1c
    136 Nc0a2298c0d014c2fbc5d7a596306f4f7 rdf:first sg:person.01306226720.74
    137 rdf:rest Nb422d8998da845668eb2643ec6e70760
    138 Nc4aa5e5718514f41ad584edcd55bfc1c rdf:first sg:person.01167077171.09
    139 rdf:rest rdf:nil
    140 Nd98c0de684bc44de9b601fabc2ad2798 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    141 schema:name Antimetabolites, Antineoplastic
    142 rdf:type schema:DefinedTerm
    143 Nd9ae0db071084cd9a847b24eefd44579 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    144 schema:name Humans
    145 rdf:type schema:DefinedTerm
    146 Ndfb3e34f38184631a26778aba596b842 schema:name dimensions_id
    147 schema:value pub.1039960563
    148 rdf:type schema:PropertyValue
    149 Ne2b7c560140f42b7b24d72c313d08851 schema:issueNumber 6
    150 rdf:type schema:PublicationIssue
    151 Neaa8edd2e63c458092482b4c92cb8e2a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    152 schema:name Decitabine
    153 rdf:type schema:DefinedTerm
    154 Nf5affb9d594c48c6868390fe641681e6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    155 schema:name Myelodysplastic Syndromes
    156 rdf:type schema:DefinedTerm
    157 Nfe488ce8dee141f78aa3c5c06fb57653 schema:volumeNumber 69
    158 rdf:type schema:PublicationVolume
    159 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    160 schema:name Medical and Health Sciences
    161 rdf:type schema:DefinedTerm
    162 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
    163 schema:name Cardiorespiratory Medicine and Haematology
    164 rdf:type schema:DefinedTerm
    165 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
    166 schema:name Clinical Sciences
    167 rdf:type schema:DefinedTerm
    168 sg:journal.1088364 schema:issn 0344-5704
    169 1432-0843
    170 schema:name Cancer Chemotherapy and Pharmacology
    171 schema:publisher Springer Nature
    172 rdf:type schema:Periodical
    173 sg:person.010061377417.22 schema:affiliation grid-institutes:grid.413591.b
    174 schema:familyName Wijermans
    175 schema:givenName Pierre W.
    176 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010061377417.22
    177 rdf:type schema:Person
    178 sg:person.01107523720.19 schema:affiliation grid-institutes:None
    179 schema:familyName Rosing
    180 schema:givenName Hilde
    181 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01107523720.19
    182 rdf:type schema:Person
    183 sg:person.01167077171.09 schema:affiliation grid-institutes:grid.5477.1
    184 schema:familyName Beijnen
    185 schema:givenName Jos H.
    186 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01167077171.09
    187 rdf:type schema:Person
    188 sg:person.01306226720.74 schema:affiliation grid-institutes:None
    189 schema:familyName Keizer
    190 schema:givenName Ron J.
    191 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01306226720.74
    192 rdf:type schema:Person
    193 sg:person.013575273137.17 schema:affiliation grid-institutes:grid.5477.1
    194 schema:familyName Schellens
    195 schema:givenName Jan H. M.
    196 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013575273137.17
    197 rdf:type schema:Person
    198 sg:person.0647446717.15 schema:affiliation grid-institutes:None
    199 schema:familyName Jansen
    200 schema:givenName Robert S.
    201 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0647446717.15
    202 rdf:type schema:Person
    203 sg:pub.10.1007/978-1-4684-1248-2_24 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033527280
    204 https://doi.org/10.1007/978-1-4684-1248-2_24
    205 rdf:type schema:CreativeWork
    206 sg:pub.10.1007/bf00686478 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014009072
    207 https://doi.org/10.1007/bf00686478
    208 rdf:type schema:CreativeWork
    209 sg:pub.10.1007/bf00694338 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023618222
    210 https://doi.org/10.1007/bf00694338
    211 rdf:type schema:CreativeWork
    212 sg:pub.10.1007/bf01696231 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005652888
    213 https://doi.org/10.1007/bf01696231
    214 rdf:type schema:CreativeWork
    215 sg:pub.10.1007/s00277-005-0004-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023684211
    216 https://doi.org/10.1007/s00277-005-0004-1
    217 rdf:type schema:CreativeWork
    218 sg:pub.10.1007/s00280-002-0563-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1075257700
    219 https://doi.org/10.1007/s00280-002-0563-y
    220 rdf:type schema:CreativeWork
    221 sg:pub.10.1007/s00280-007-0531-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019990216
    222 https://doi.org/10.1007/s00280-007-0531-7
    223 rdf:type schema:CreativeWork
    224 sg:pub.10.1007/s00280-008-0750-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052771263
    225 https://doi.org/10.1007/s00280-008-0750-6
    226 rdf:type schema:CreativeWork
    227 sg:pub.10.1007/s002800050832 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023712398
    228 https://doi.org/10.1007/s002800050832
    229 rdf:type schema:CreativeWork
    230 sg:pub.10.1038/sj.leu.2400526 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004603814
    231 https://doi.org/10.1038/sj.leu.2400526
    232 rdf:type schema:CreativeWork
    233 sg:pub.10.1038/sj.leu.2400550 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034237061
    234 https://doi.org/10.1038/sj.leu.2400550
    235 rdf:type schema:CreativeWork
    236 sg:pub.10.1186/1471-2407-8-128 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027980014
    237 https://doi.org/10.1186/1471-2407-8-128
    238 rdf:type schema:CreativeWork
    239 grid-institutes:None schema:alternateName Department of Pharmacy and Pharmacology, Slotervaart Hospital/The Netherlands Cancer Institute, Louwesweg 6, 1066 EC, Amsterdam, The Netherlands
    240 schema:name Department of Pharmacy and Pharmacology, Slotervaart Hospital/The Netherlands Cancer Institute, Louwesweg 6, 1066 EC, Amsterdam, The Netherlands
    241 rdf:type schema:Organization
    242 grid-institutes:grid.413591.b schema:alternateName Department of Haematology, Haga Hospital, Leyweg 275, 2545 CH, The Hague, The Netherlands
    243 schema:name Department of Haematology, Haga Hospital, Leyweg 275, 2545 CH, The Hague, The Netherlands
    244 rdf:type schema:Organization
    245 grid-institutes:grid.5477.1 schema:alternateName Department of Pharmaceutical Sciences, Science Faculty, Utrecht University, Universiteitsweg 99, 3584 CG, Utrecht, The Netherlands
    246 schema:name Department of Pharmaceutical Sciences, Science Faculty, Utrecht University, Universiteitsweg 99, 3584 CG, Utrecht, The Netherlands
    247 Department of Pharmacy and Pharmacology, Slotervaart Hospital/The Netherlands Cancer Institute, Louwesweg 6, 1066 EC, Amsterdam, The Netherlands
    248 Division of Medical Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands
    249 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...